Arvinas has entered a partnership with Novartis for the development and global licensing of ARV-766, Arvinas' second-generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. This venture also led to the sale of Arvinas' AR-V7 preclinical program to Novartis.
As per the agreement, Novartis will be responsible for the development and commercialization of ARV-766 and will receive R&D, manufacturing, and commercialization rights for the preclinical AR-V7 program. Arvinas will be paid a USD 150 million upfront payment for the two programs and up to USD 1.01 billion in payments for development, regulatory, and commercial milestones and tiered royalties for ARV-766.
Arvinas is a clinical-stage biotechnology company specializing in developing therapies using its proprietary Proteolysis-Targeting Chimera (PROTAC) technology, which aims to degrade disease-causing proteins. Arvinas’ main focus is on oncology and neuroscience, with key drug developments including ARV-110 (Bavdegalutamide) for prostate cancer and ARV-471 for breast cancer currently in clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.